Russo D, Manole D, Arturi F, Suarez H G, Schlumberger M, Filetti S, Derwahl M
Dipartimento di Scienze Farmacobiologiche, Università di Catanzaro, Italy.
Thyroid. 2001 Jan;11(1):37-9. doi: 10.1089/10507250150500649.
Decrease or loss of the sodium iodide (Na+/I-) symporter (NIS) activity influences the suitability of using radioiodine to detect and treat metastatic thyroid tissues. In previous studies, the presence of the NIS transcript, albeit at lower expression levels, has been shown in most thyroid differentiated carcinomas. In this study we searched for point mutations or other genetic alterations that may be responsible for an altered function of the NIS protein in tumors that still express NIS transcripts. Tumoral cDNAs derived from seven differentiated thyroid carcinomas (DTC), five papillary and two follicular, were analyzed by direct sequencing after polymerase chain reaction (PCR) amplification of the structural gene of the Na+/I- symporter. Neither mutations nor other genetic abnormalities were detected in any tumor sample examined. The data indicate that mutations or other genetic alterations of the NIS structural gene are not a major cause of the reduced iodide uptake in DTC.
碘化钠（Na⁺/I⁻）同向转运体（NIS）活性的降低或丧失会影响使用放射性碘检测和治疗转移性甲状腺组织的适用性。在先前的研究中，大多数甲状腺分化癌中已显示存在NIS转录本，尽管表达水平较低。在本研究中，我们寻找可能导致仍表达NIS转录本的肿瘤中NIS蛋白功能改变的点突变或其他基因改变。在对Na⁺/I⁻同向转运体结构基因进行聚合酶链反应（PCR）扩增后，通过直接测序分析了来自7例分化型甲状腺癌（DTC）（5例乳头状癌和2例滤泡状癌）的肿瘤cDNA。在所检查的任何肿瘤样本中均未检测到突变或其他基因异常。数据表明，NIS结构基因的突变或其他基因改变不是DTC中碘摄取减少的主要原因。
